Some patients with advanced colorectal cancer that once carried a grim prognosis are now alive three years after starting a two-drug immunotherapy regimen. The FDA approved nivolumab plus ipilimumab as a first-line treatment for metastatic colorectal cancer with deficient mismatch repair, or dMMR, and high microsatellite instability, known as MSI-H. The approval rested on trial data showing that a meaningful share of patients remained alive without disease progression at the three-year mark, a benchmark that would have been unthinkable for this population a decade ago.
Why dMMR colorectal cancer patients now have a three-year survival benchmark
Colorectal cancer with dMMR or MSI-H status accounts for a minority of all cases, but these tumors generate large numbers of mutations that make them visible to the immune system. That biological feature made them strong candidates for checkpoint inhibitors, drugs that release the brakes on immune cells. The combination of nivolumab, which blocks PD-1, and ipilimumab, which blocks CTLA-4, attacks two separate immune checkpoints at once. The FDA decision for first-line advanced dMMR/MSI-H colorectal cancer followed pivotal evidence reporting a three-year benchmark outcome, meaning a substantial proportion of patients had not progressed years after treatment began.
For patients and oncologists, this result changes the calculus of first-line treatment decisions. Before dual checkpoint blockade entered the picture, standard chemotherapy combinations were the default, and long-term disease control was rare in the metastatic setting. The three-year data point signals that some patients may achieve durable remissions rather than temporary responses that fade within months.
Clinically, this has several implications. Oncologists now discuss immunotherapy up front when a newly diagnosed metastatic patient is found to have dMMR or MSI-H disease. Molecular testing of tumor tissue, once considered optional in some practices, becomes essential to identify who might benefit from nivolumab plus ipilimumab. Patients eligible for this approach may be able to avoid or delay the toxicities of intensive chemotherapy, such as neuropathy and severe gastrointestinal side effects, while still aiming for long-term disease control.
The durability of benefit also reshapes expectations around quality of life. Many patients treated with dual checkpoint blockade who remain progression-free at three years are off active treatment or on reduced schedules, managing mostly immune-related side effects rather than continuous chemotherapy. This does not mean cure is assured, but it introduces the possibility of extended, treatment-light periods that were rarely achievable in metastatic colorectal cancer.
Targeted combinations reshaping outcomes across CRC subtypes
The nivolumab-ipilimumab result is not an isolated advance. Several other drug pairings have demonstrated meaningful survival gains in molecularly defined subsets of metastatic colorectal cancer. The FDA approved tucatinib with trastuzumab for HER2-positive metastatic colorectal cancer, with follow-up data showing patients alive at approximately two years after starting treatment. HER2-positive disease represents another small but identifiable slice of the colorectal cancer population that had few effective options before targeted therapy.
In this HER2-driven subgroup, tumors overexpress the HER2 protein or harbor HER2 gene amplification, making them susceptible to drugs that block HER2 signaling. Tucatinib is a small-molecule inhibitor that selectively targets the HER2 kinase, while trastuzumab is a monoclonal antibody that binds the extracellular domain of HER2. Their combined use capitalizes on dual HER2 blockade, a strategy borrowed from breast cancer, to shrink tumors and delay progression. For patients whose disease had progressed on standard chemotherapy, the ability to achieve disease control over a span of years rather than months represents a major shift.
In the refractory setting, where patients have already failed multiple lines of chemotherapy, the combination of trifluridine/tipiracil (Lonsurf) plus bevacizumab (Avastin) improved median progression-free survival and overall survival compared with chemotherapy alone, according to the National Cancer Institute. While the absolute gains were more modest than those seen with checkpoint inhibitors in dMMR disease, they offered a measurable extension of life for patients who had exhausted standard treatments.
Trifluridine/tipiracil is an oral cytotoxic agent that interferes with DNA synthesis, while bevacizumab targets vascular endothelial growth factor (VEGF) to inhibit tumor blood vessel formation. Together, they appear to slow tumor growth more effectively than trifluridine/tipiracil on its own. In practice, this regimen provides a new standard option for patients in later lines of therapy, where historically choices were limited and expected survival was short.
A separate phase 3 trial published in The New England Journal of Medicine showed that adding atezolizumab to the mFOLFOX6 chemotherapy regimen improved three-year disease-free survival in patients with resected stage III dMMR colon cancer. That trial addressed an earlier stage of disease, not the metastatic setting, but it reinforced the principle that immunotherapy can produce durable benefit when paired with the right molecular profile. For patients with high-risk, surgically removed tumors, combining chemotherapy with checkpoint blockade may reduce the likelihood of recurrence and potentially increase the chance of cure.
The MSS gap and ongoing trials testing new combinations
The largest unresolved question is whether similar results can be achieved in microsatellite-stable, or MSS, colorectal cancer, which accounts for the vast majority of cases. MSS tumors are generally resistant to checkpoint inhibitors used alone, and no immunotherapy combination has yet won regulatory approval for this population. The immune microenvironment in MSS disease tends to be “cold,” with fewer infiltrating T cells and more suppressive signals that blunt immune attack.
Researchers are testing whether adding a targeted agent to an immune checkpoint inhibitor can overcome that resistance. The STELLAR-303 trial, a phase 3 study registered on ClinicalTrials.gov, is comparing XL092 (zanzalintinib), a MET and VEGFR inhibitor, combined with atezolizumab against regorafenib in patients with MSS or MSI-low metastatic colorectal cancer who have already received standard therapies. XL092 is designed to interfere with tumor growth and angiogenesis, potentially altering the tumor microenvironment in ways that make it more receptive to immune attack.
Separately, the INTRINSIC trial includes an atezolizumab plus tiragolumab arm in a metastatic colorectal cancer cohort, testing whether dual PD-1/PD-L1 and TIGIT blockade can produce responses in defined CRC subpopulations. Tiragolumab targets TIGIT, an inhibitory receptor on T cells and natural killer cells, and blocking it may enhance anti-tumor immunity when combined with PD-L1 inhibition.
The hypothesis driving both trials is that blocking an angiogenesis or immune co-inhibitory pathway alongside a checkpoint inhibitor can convert cold MSS tumors into ones the immune system can attack. If either trial succeeds, the three-year disease control rates seen in dMMR patients could extend to a far larger group. But the path forward is uncertain: previous attempts to sensitize MSS tumors to immunotherapy by pairing checkpoint inhibitors with other targeted agents or chemotherapy have yielded mixed or modest results.
For now, the therapeutic landscape of metastatic colorectal cancer is defined by molecular stratification. Patients with dMMR or MSI-H disease may receive dual checkpoint blockade in the first-line setting, with a realistic chance of remaining progression-free for years. Those with HER2-positive tumors can pursue HER2-directed combinations that extend survival beyond what chemotherapy alone could offer. In later lines, regimens such as trifluridine/tipiracil plus bevacizumab provide incremental gains for a broader group of patients.
The challenge is to translate these successes into effective strategies for the much larger MSS population. As trials like STELLAR-303 and INTRINSIC mature, they will test whether rationally designed combinations can finally crack the resistance of MSS disease. Until then, the three-year survival benchmark achieved in dMMR colorectal cancer serves both as a proof of principle for immunotherapy and as a reminder of the work still needed to bring comparable outcomes to all patients with this common and often lethal cancer.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
